Cytokinetics
Clinical trials sponsored by Cytokinetics, explained in plain language.
Biopharmaceutical company focused on muscle biology and cardiac muscle diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New heart drug aficamten challenges standard Beta-Blocker in major trial
Disease control CompletedThis study tested a new drug called aficamten against the standard medicine metoprolol in 175 adults with a heart condition that makes the heart muscle thick and blocks blood flow. The goal was to see which drug better improves exercise ability and symptoms like shortness of brea…
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill aims to help heart patients breathe easier and move more
Disease control CompletedThis Phase 3 trial tested a daily pill called aficamten in 282 adults with a type of thickened heart muscle that blocks blood flow and causes symptoms like shortness of breath and chest pain. Participants received either aficamten or a placebo for 24 weeks. The main goal was to s…
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New heart pill aims to ease thick heart muscle symptoms
Disease control CompletedThis study tested a new daily pill called CK-3773274 (aficamten) in 96 adults with symptomatic hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The goal was to find the right dose and check safety, including effects on heart pumping strength. P…
Phase: PHASE2 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC